Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
da-9801 (1 trial)
Diabetic Neuropathies (Phase 2)
Peripheral Nervous System Diseases (Phase 2)
Trials (1 total)
Trial APIs (1 total)